Breastfeeding Supplies Market - Outlook, and Opportunity Analysis, 2018-2026

Breastfeeding supplies are the apparatus used for taking out the milk from the breast. Breastfeeding supplies are used to pump and store the milk for later use. These breastfeeding supplies allow the consumer to pump the breast milk into bags or storage bottles. Certain supplies such as breast pumps, storage bottles and teats, and sippers are used for breastfeeding purpose and act in different ways.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2747

Breast pump is a suction instrument for withdrawing milk from breast. Breast pumps are used primarily for relief from breast pain and for babies who are unable to suck milk. Breast pump can be the great resource for breastfeeding working moms. It can give some flexibility with feedings.

The global breastfeeding supplies market size was valued at US$ 1,445.5 million in 2017 and is expected to exhibit a CAGR of 7.1% over the forecast period (2018 – 2026).

Increasing number of working women and nuclear families propel the global breastfeeding supplies market growth

Increasing number of working women is expected to increase the demand for breastfeeding supplies, which in turn is expected to fuel the global breastfeeding supplies market growth in the near future. Shorter maternity period to new mothers and willingness of mothers to provide full nutrition to their children is another factor fueling the market growth. For breastfeeding moms, manufacturers introduced new products, including breast milk supply and breastfeeding support to support the moms and their growing families. For instance, in January 2019, Medela LLC launched the new research-based PersonalFit Flex breast shields to help mothers pump over 11% more breast milk faster.

Market Dynamics

Increasing prevalence of multiple births, women employment, geographical expansion of global breastfeeding supplies manufacturers in North America, and increasing investment in healthcare infrastructure by manufacturers are some of the major factors that are expected to drive the market growth. Furthermore, rising women employment drives the growth of global breastfeeding supplies market. For instance, according to the International Labor Organization in 2018, female employment in emerging economies has increased to 46.6% as compared to 2017. However, the high cost of development to develop new devices and lengthy regulatory approval processes are expected to hamper the global breastfeeding supplies market.

Key Players

Major players operating in the global breastfeeding supplies market include Medela LLC, Hygeia, Philips Avent, Spectra Baby USA, Nuby, Ameda, Nestle Gerber, Mayborn USA, Evenflo Feeding, ARDO, Pigeon, and NUK USA

Browse Complete Report For More Information @ https://www.coherentmarketinsights.com/market-insight/breastfeeding-supplies-market-2747

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Cell Therapy Manufacturing Market - Outlook, and Opportunity Analysis, 2018-2026

Cell therapy is one of the most promising healthcare procedure for restoration of damaged tissue. Cell therapies have huge potential for the wide range of disease treatment including tissue degradation, immune deficiency, metabolic disorders, and cancer. Cell therapy are categorized into two type’s allogeneic (cells from third party donor) and autologous (cells from one’s own body). Cell therapy has gained significant traction in recent past and currently it under commercial development. Main objective of cell therapy is to re-establish the lost function of tissues and cells rather than to produce a new organ. Some cell therapies have been established and permitted for clinical trial. For instance, in 2013 a stage 2 clinical trial was completed for transplantation of bone marrow derived stem cells in affected knee by rheumatoid arthritis. The growth of this technique is also increased due to involvement of the government agencies. For instance, innovate U.K. 2014 report showed that government agreed to fund US$15.3 million in cell therapy manufacturing market.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1728

Cell Therapy Manufacturing Market Dynamics

Increasing number of surgical procedures performed across the world coupled with increasing number of trauma and accidents is propelling demand for new medical therapy. For instance, according to a 2015, World Health Organization (WHO) report, more than 50,000 stem cell transplants are carried out annually worldwide for various surgeries. Stem cells transplantation is promising medical therapy for patients with advance stage diseases like Alzheimer’s, arthritis, autism, blindness, cancer, cerebral palsy, diabetes etc. Key biopharmaceutical companies are majorly investing in research for cell therapy. For instance, Longeveron LL, a biopharmaceutical company received a US$ 750,000 grant from the Maryland Technology Development Corporation (TEDCO) in 2018 for stem cell therapy research. These collaborations and government funding are boosting growth of the cell therapy manufacturing market. However, the strict regulations, guidelines, and various health safety concerns over cell therapy treatment are restraining growth of the cell therapy market.

Cell Therapy Manufacturing Market - Regional Insights

On the basis of the region, the global cell therapy market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds the dominant position in the global cell therapy manufacturing market, owing to large number of surgeries performed in the region as well as development of technologically advanced products for therapy. According to the National Health Statistics Report by the Centers for Disease Control & Prevention (CDC), around 201,748.3 million surgical and non-surgical procedures were performed in the U.S. in 2011.

Furthermore, Asia Pacific is projected to witness significant growth in the global cell therapy manufacturing market in the near future. Marginal market share would be grabbed by the local players entering into market due to less stringent regulatory requirements and growing customer pool prone to various chronic and infectious disease such as cancer, HIV, hepatitis etc. Therefore induction of cell therapy can provide better solutions to the patient at the marginally lower cost.

Cell Therapy Manufacturing Market - Competitive Insights

The key player operating in the global cell therapy manufacturing market include, Pharmicell, Merck Group, Dickinson and Company, Thermo Fisher, Lonza Group, Miltenyi Biotec GmBH, Takara Bio Group, STEMCELL Technologies, Cellular Dynamics International, Becton, Osiris Therapeutics, Bio-Rad Laboratories, Inc., Anterogen, MEDIPOST, Holostem Terapie Avanazate, Pluristem Therapeutics, Brammer Bio, CELLforCURE, Gene Therapy Catapult EUFETS, MaSTherCell, PharmaCell, Cognate BioServices and WuXi AppTec. Key players are adoption growth strategies such as collaborations, introduction of new technologies and devices to maintain dominant position in the market. For instance, in 2014, ViaCyte, Inc. successfully implanted VC-01 an embryonic stem cell derived islet for the treatment of type 1 diabetes.

Browse Complete Report For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/cell-therapy-manufacturing-market-1728

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Digital Stethoscope Market - Outlook, and Opportunity Analysis, 2018-2026

Digital Stethoscope is a modern technology device that transforms acoustic sound into electronic signals, which further can be amplified for ideal listening. Electronic signals can be further digitalized and processed to transmit them in to a laptop or personal computer. The digital stethoscope consists of three different modules i.e. data acquisition, pre- processing, and signal processing. Data acquisition model consists of piezoelectric sensor and microphone. This module is responsible for buffering, amplification, and filtering of auscultated sounds whereas it is also responsible for conversion of acoustic sound to digital signal. Pre-processing module is responsible for filtering digital signals to remove any artifacts. Signal processing module helps in packaging of information in high order classification and helps in clustering of the data for a diagnostic decision. Currently available digital stethoscopes allows user to select different frequency response modes, which allows listener to efficiently examine sounds from lungs, heart, and other body parts. For instance, the 3M Littmann Stethoscopes Range consists of piezoelectric sensor, which helps to reduce ambient noise using adaptive noise canceller and allows amplification of sound up to 24 times. An advanced digital stethoscope helps to stream heart sounds on smart phones as well.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/1711

Digital Stethoscope Market Drivers:-

Advancement in technology such as development of electronic stethoscope with Bluetooth wireless capability is expected to be one of the major drivers of growth of digital stethoscope market. Digital stethoscopes offer various advantages as compared to the manual stethoscopes. One of the major advantages is that digital stethoscopes have the ability to amplify sounds, as well as observe the received sounds on a visual display. Some Stethoscopes are also capable of recording and replaying the captured video or audio, which helps practitioners or physicians to maintain patients’ medical data. A new product, Steth IO has been launched by Steth IO, a U.S.-based company, in April 2018. Steth IO is a smart phone based digital stethoscope. It can be used exclusively on iPhones (module 6 and above). This device helps doctor to listen and also measure heart rates or lung sounds just by operating an app on phone and by placing it close to the patient’s chest. This device was approved by Food and Drug Administration (FDA) in 2016. This product does not require batteries or chargers as it draws power directly from the iPhone. This device also helps physicians to keep a record of the patient’s medical data, add flag clips, or notes within the recordings.

Other factors such as increasing number of patients suffering from cardiovascular disorders, improved diagnosis due to advantages provided by digital stethoscope, and increasing awareness among population regarding use of digital stethoscope are expected to boost growth of the digital stethoscope market. According to a study conducted by Centers for Disease Control and Prevention (CDC), in 2017, in the U.S. around 735,000 people are suffering from cardiovascular disorders, which is in turn fueling growth of the market.

However, high cost of the digital stethoscope as compared to conventional stethoscope may hinder growth of the market.

Digital Stethoscope Market Regional Analysis:-

North America is expected to hold dominant position in global digital stethoscope market, owing to the availability of innovative products in the region. In 2009, the 3M Company, a U.S.-based company launched first electronic stethoscope with Bluetooth wireless capacity. 3M Littman Electronic Stethoscope model 3200 paired with new zargis medical software helps in detecting heart murmurs. Bluetooth technology of this device helps to transfer lungs, heart, and other sounds of the body directly to the software for further analysis. This device consists of 2 software i.e. Zargis Cardio scan software and Zargis Steth Assist Software. Zargis cardio scan software easily pairs with the device to help the doctor diagnose four main cardiac sites, after one minute the device provides report about the patient’s heart condition indicating all the problems observed. Europe is expected to witness significant growth over the forecast period, owing to launches of novel products in the region. For instance, in 2015, Ekuore a Spain-based company launched eKuore Pro Stethoscope, a wireless stethoscope. The company also has a product named eKuore stethoscope for hearing loss, which can be used by doctors who are have a problem in hearing or are deaf, as they have hearing aids connected to them.

Browse Complete Report For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/digital-stethoscope-market-1711

Digital Stethoscope Market Key Players:-

Major players operating in digital stethoscope market include Eko Devices, FarmaSino Pharmaceuticals, Contec Medical Systems, Qufu Longer Care Meditech Limited, Exanovo Group, Think Labs Medical LLC, Sensi Cardiac, and 3M. Eko Devices has two digital stethoscope devices named as CORE and DUAL. CORE has 40x sound amplification, which can work with all stethoscopes and delivers loud and clear sound of heart and lungs. DUO is a combination of EKG and electronic stethoscope. It is a portable and hand held device, which provides review of the heart sounds and rhythms in an accompanying software.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Digital Medicines Market - Trends, Outlook, and Opportunity Analysis, 2018-2026

Information technology has introduced age of digital medicine, and growing number of tradition and non-traditional IT companies are stepping into new healthcare tools and service. Digital medicine refers to use of evidence based technology and product that rely on health information to diagnose, prevent, monitoring or treat disease and disease conditions. Technologies such as telemedicine are redefining how doctors and patients interact. Digital medicine technology is more privileged then current medical practice since it is more precise and effective technology. In 2017 first digital pill was approved by U.S. food and drug administration (FDA) in the U.S. which tracks if patients have taken their medication.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2749

Digital Medicines Market - Drivers

Digital medicine market is expected to witness significant growth during the forecast period, owing to high usage of smart phone. The use of mobile devices by health care professionals (HCPs) has transformed many aspects of clinical practice. Mobile devices have become commonplace in health care settings, leading to rapid growth in the development of medical software applications (apps) for these platforms. For instance, according to Pew Research Center 2019 data, mobile technology has spread rapidly around global. It estimate that more than 5 billion people have smart phones globally.

Rising awareness of personalized healthcare factor is drive the digital medicine market growth during he forecast period. For instance, according to Dosis Personalized and Digital Medicine Consumer Report surveyed in 2019 more than 1,000 consumers, weighted for the U.S. population, to gain a better understanding between the advances in personalized medicine approaches and general consumer awareness of its benefits.

Digital Medicines Market-Regional Analysis

On the basis of region, the digital medicine market is segmented into North America, Latin America, Europe, Asia pacific, Middle East, and Africa. North America dominates the digital medicine market during the forecast period, increasing prevalence of chronic disease. For instance, according to National Center for Biotechnology Information (NCBI) 2018 report, chronic diseases are among the most prevalent and costly health conditions in the United State around 133 million Americans suffer from at least one chronic disease.

Asia pacific is expected to witness significant growth over the forecast period, owing to rising expenditure in digital healthcare. For instance, according to China Digital Health Care Revolution 2015 reports, in 2014 approximately $700 million in venture funding poured into digital healthcare in china, with investors supporting all thing digital e-commerce to online physician and patient communication service.

Browse Complete Report For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/digital-medicines-market-2749

Digital Medicines Market-Competitive Landscape

Key player operating in the digital medicine market include i2Morrow Inc., Ginger.io Inc., Akili Interactive Labs, Livongo Health, AliveCor Inc., WellDoc Inc., Mocacare, Proteus Digital Health Inc.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Antiepileptic Drugs Market – Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

Epilepsy is associated with disrupted activities in the brain called seizures, which affects the central nervous system. Epilepsy is categorized into generalized seizures and partial seizures based on the areas affected in the brain. Generalized seizures affect the whole brain, while partial seizures affect just one part of the brain. Seizures are further classified into mild seizures and stronger seizures depending on the severity of the seizures. The diagnosis of mild seizures are difficult, as its lasts only for few seconds. Stronger seizures may last for a few seconds to several minutes, resulting in spasms and uncontrollable muscle twitches. This may cause the patient to lose consciousness, lead to temporary loss of cognition, or memory loss during the seizure. Epilepsy occurring due to brain infections such as meningitis is known as symptomatic epilepsy, while genetics related condition is called idiopathic epilepsy.

Request PDF Brochure Of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1701

The number of available antiepilepsy drugs have doubled over the past few decades and for the treatment of pediatric epilepsy, nine new drugs were launched in the last decade, as the benefits of the medicines are greater than the subsequent side-effects from the medicine. Third generation epilepsy drugs are rapidly replacing second and first generation drugs, as they are more safe and tolerable than the previous generation drugs. Few first generation drugs are Phenytoin (Dilantin and Phenytek), Carbamazepine (Carbatrol), Valproate (Depakote), Oxycarbazepine (Trileptal), Phenobarbital (Luminal), Primidone (Mysoline); and second generation drugs are Lamotrigine (Lamictal), Pregabalin (Lyrica), Lacosamide (Vimpat), and Rufinamide (Banzel/Inovelon). The newer drugs have better efficacy, with much better pharmacokinetic profiles and fewer drug interactions than the classic first generation drugs. For instance, the third generation drugs, UCB’s Keppra (levetiracetam) and GlaxoSmithKline’s (GSK’s) Lamictal (lamotrigine) have rapidly become the commonly used drugs for first-line treatments.

Antiepileptic Drugs Market Drivers

Factors such as rising prevalence of epilepsy and robust pipeline are expected to boost the market growth over the forecast period. According to the study by Epilepsy Action Australia statistics in 2017, around 50 million people globally have epilepsy with around 80% of the people living in emerging economies such as India, Brazil, and China. Moreover, according to the Centers for Disease Control and Prevention, in 2017, an estimated 3.4 million people have active epilepsy in the U.S., which includes 3 million adults and 470,000 children. Manufacturers have potential drug molecules in the pipeline for the treatment of various forms of epilepsy. For instance, SK Life Sciences, Inc. has Cenobamate (YKP3089) in Phase 3 clinical trials. Eisai, Co., Ltd. has the drug Perampanel in Phase 2 clinical trials, and Marinus Pharmaceuticals, Inc. has the drug Ganaxolone in Phase II clinical trials. The expected launches of these drugs over the forecast period is expected to create favorable condition for the market growth. Moreover, in 2015, Neurelis, Inc. received orphan drug designation for NRL-1 for the treatment of acute repetitive seizures and the drug is currently in phase III clinical trials. In 2016, Pfizer, Inc.’s Lyrica (pregabalin) cleared phase-3 clinical trials for prescription to pediatric patients. Drug launches by leading manufacturers is expected to foster growth of the antiepileptic drugs market over the forecast period. For instance, in 2016, UCB Pharma Limited received the U.S. FDA approval for Briviact, for the treatment of patients with partial onset seizures. Mylan launched generic Felbatol tablets in the U.S. after receiving approval from the U.S. Food & Drug Administration in 2016. These factors are expected to boost the market growth over the forecast period.

However, mild neurological adverse effects shown by these drugs can be fatal and the adverse reactions and risks vary with each medication, which is expected to hamper the adoption rate of the antiepileptic drugs over the forecast period, in turn affecting the market growth.

Antiepileptic Drugs Market Regional Analysis

North America and Europe are expected to witness significant growth in the market over the forecast period due to robust pipeline for epilepsy treatment and individual efforts by leading manufacturers. For instance, Pfizer, Inc. entered into partnership with Epilepsy Foundation to find solutions for generic forms of epilepsy and associated neurological disorders in 2014. Asia Pacific region is expected to show positive developments over the forecast period, owing to drug launches by leading manufacturers in the region. For instance, UCB Pharma received approval in Japan for Vimpat adjunctive therapy for partial onset seizures of epilepsy in 2016. Moreover, Eisai Pharma launched antiepilepsy drug Fycompa in India in 2017.

Browse Complete Report For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/antiepileptic-drugs-market-1701

Antiepileptic Drugs Market Competitive Landscape

Key players operating in the global antiepileptic drugs market include GlaxoSmithKline plc, Johnson & Johnson, Valeant Pharmaceuticals International, Inc., Abbott Laboratories, Cephalon, Inc., Pfizer, Inc., Sunovion Pharmaceuticals, Inc., Novartis AG, UCB Pharma Ltd., and Sanofi S.A.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Soft Tissue Repair Market – Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

Human body soft tissue comprises tendons, muscles, ligaments, skin, nervous tissue, cartilage, and synovial membrane. Tissue damage causes change in structure and biochemical composition. Soft tissue repair refers to replacement of the destroyed body tissue with living tissue and it is segmented into two categories namely repair and regeneration. In repair, the lost tissue is replaced by granulated tissue, which further matures to form a scar tissue. Repair is further divided into four phases – bleeding, inflammation, proliferation and re-modelling of the tissue. Regeneration is the process in which healing takes place by proliferation of the residual cells i.e. the cells which are not injured. It usually results in complete restoration of the original tissue. Surgery of soft tissue repair comprises of some procedures in which devices such as sutures, anchors, grafts, and others are usually used to reshape, remodel or fix the damaged tissue. These procedures restore functionality of the damaged tissue.

Request PDF Brochure Of Research Report:https://www.coherentmarketinsights.com/insight/request-pdf/1694

Soft Tissue Repair Market Drivers: -

Growth in soft tissue repair market can be attributed to several soft injuries in field of sports. Increasing number of people participating in sports is resulting into increase in the number of injuries, which is expected further boost growth of the of soft tissue market. Some of the injuries which affect sports people are strains, contusions, sprains, tendinitis, etc. According to a survey conducted by National Committee of Soccer Physicians (CNMF) in 2015, around 47% of players were injured with different muscle injuries such as hamstring injuries, muscle dysfunction, etc. According to California State Athletic Commission (CSAC), one of the most common injuries among the athletes is Traumatic Brain Injury (TBI). Increasing awareness regarding treatment of such injuries, as these injuries can affect their performance in future is driving growth of the market. According to the survey conducted by American Time Use Survey (ATUS), in 2015, there is rise of 3.6% of people participating in sports annually. According to ATUS, on an average day men participating in sports is around 4.9% and women participating in sports is around 2.3%. India has various schemes for sports such as Khelo India, National Sports Development Fund, and Scheme for promotion of sports among persons with disabilities, etc. According to Khelo India Program, 1000 students are selected every year, and they are offered a sponsorship of 5 lakhs for 8 years. Such huge participation in sports is expected to boost the growth of global tissue repair market. Increase in the number of geriatric population is also expected to drive growth of the market, as they demand for good quality of life. Old population is susceptible to problems such as trauma, joint replacement, and fractures, which can cause pain and uneasiness. According to the Census conducted in Europe in 2016, there is an increase of 4.3% in geriatric population as compared to the former years. This can further result in increment of patients for soft tissue repair surgeries and joint replacement. Moreover, increasing number of accidents is boosting growth of the market. According to a study conducted by US Department of Transportation in 2015, road accident incidents have been increased by 3.8%.

Soft Tissue Repair Market Regional Analysis:-

According to the European Union government legislature, European government will be spending almost 80 billion Euros on Research and Development to enhance a broad range of research projects. According to American Joint Replacement Registry (AJRR), around 75% increase in hospitals was reported and 41% increase in the number of surgeons from the year 2012 -2015, hence there is an increment of 102% in the number of cases related to joint replacement. This can increase the revenue of soft tissue repair market to a greater extent.  According to Association of South East Asia Nations (ASEAN), Asia Pacific is the fastest growing market for medical technology market. In 2016, 105 – 120 million medical tourists visited Asia Pacific regions to seek healthcare services. Medical Tourism of India accounts for 25% of the healthcare sector revenue. National Institute of Health (NIH) from the U.S. is the key contributor of soft tissue repair market. According to American cancer society, out of 252,710 cases of breast cancer, more than half of them have opted for breast reconstruction. North America region is gaining significant traction in the soft tissue repair market by manufacturing new products such as EZ Derm by Molnlycke Healthcare, this product is used to dress wounds using pins and wires together or independently with other fixation devices. These devices are used in spine and hip replacement surgeries.

Browse Complete Report For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/soft-tissue-repair-market-1694

Soft Tissue Repair Market Key players:-

One of the commonly used product for soft tissue reconstruction is XCM BIOLOGIC from DePuy Synthes. It is a biologic tissue used to repair abdominal wall, it also repairs the defect of thoracic wall and hernia surgery. Other uses include muscle flap reinforcement, soft tissue reconstructive procedures, and suture line reinforcement. Key player operating in market include Life Cell Corporation, Organogenesis, Smith And Nephew, Johnson And Johnson, Covidien, Arthrex Inc, Integra Life Sciences Corporation, Stryker Medical Corporation, Wright Medical Technology, C. R. Bard, De Puy Synthes, and American Medical Systems.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Fibromyalgia Treatment Market – Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

Fibromyalgia is a common and complex chronic pain disorder that causes musculoskeletal pain, fatigue, and localized tenderness affecting individuals mentally, physically, and socially. Fibromyalgia is mainly caused due to genetic conditions, however actual cause is still unknown. The most common symptoms of fibromyalgia are fatigue, sleeping problems, chronic muscle pain, and tender points. An individual with fibromyalgia can also have symptoms such as headaches, poor concentration, and depression. Fibromyalgia symptoms might accumulate with time or it can be caused by some external factors. Fibromyalgia treatments include therapy, medications, regular aerobic exercise, stress reduction, and others. Furthermore, for treatment of fibromyalgia, antidepressants or pain medications are prescribed to treat depression, anxiety, pain, and fatigue.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/1691

Robust pipeline of novel drugs are under late clinical trial phase for treatment of fibromyalgia

Market players are focusing on active research and development, in order to introduce new products in the market and increase treatment options. Approval and launch of novel fibromyalgia treatment drugs is expected to significantly support fibromyalgia treatment market growth over the forecast period.

For instance, manufacturers such as Aptinyx, Inc., Prismic Pharmaceuticals, Inc., Innovative Med Concepts, Inc., Intec Pharma Ltd., Astellas Pharma, Inc., and others have drugs in the pipeline indicated for the treatment of fibromyalgia.

Many such drugs are in phase 2 and phase 3 of clinical trials with commercialization potential. For instance, Astellas Pharma, Inc. has ASP0819 in phase 2 and IMC-1 that received fast track designation from the U.S. FDA in 2016.

The global fibromyalgia treatment market size was valued at US$ 2,778.6 Mn in 2018 and is expected to witness a CAGR of 3.3% during the forecast period (2018 – 2026).

Market Dynamics

Key players in the market are focusing on frequent research and development activities for development of novel medications for fibromyalgia treatment. Launch of novel drugs in the market for fibromyalgia is expected to boost the fibromyalgia treatment market growth over the forecast period. For instance, drug candidate IMC-1 is being developed by Innovative Med Concepts, which received fast track designation from the U.S. FDA in 2016

In December 2018, Aptinyx Inc. announced positive results from an interim analysis of an exploratory study of its novel NMDA receptor (NMDAr) modulator, NYX-2925, in subjects with fibromyalgia. Subjects in the study received daily oral doses of NYX-2925 at two dose levels, 20 mg and 200 mg, as well as placebo, over the course of six weeks.

Market Opportunity

Currently, there are limited number of approved treatment options for fibromyalgia. Several manufacturers have potential candidates in the pipeline (some in late stages as well). Hence, new players in the market also have opportunity to develop new drug candidate for treatment of fibromyalgia.

Browse Complete Report For More Information @ https://www.coherentmarketinsights.com/market-insight/fibromyalgia-treatment-market-1691

Another opportunity is present in terms of generic drug manufacturing, as two of the drugs are expected to lose patent protection over the forecast period (Lyrica in 2019 and Savella in 2021, 2023, and 2029). Patent loss may be a restraint for the market, however, there is certainly an opportunity for generic manufacturers.

Key players operating in the fibromyalgia treatment market include Eli Lilly and Company, Pfizer, Inc., Novartis AG, Allergan plc, Sun Pharmaceutical Industries Ltd., Aptinyx, Inc., Prismic Pharmaceuticals, Inc., Innovative Med Concepts, Inc., Intec Pharma Ltd., and Astellas Pharma Inc.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Silver Sulfadiazine Market – Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027

Silver sulfadiazine is specifically used for second degree or third-degree burns on the skin, which acts ant-bacterial drug. The World Health Organization considers silver sulfadiazine as an Essential Medicines and is used as an antibiotic for skin burns. Silver sulfadiazine helps to prevent growth of yeast and bacteria and is used to treat urinary tract infections (UTI). When it is combined with pyrimethamine, the combination is used for the treatment of toxoplasmosis. Furthermore, a typical anti burn cream 1% of silver sulfadiazine contains, which is crucial to maintain as excessive quantity would make it toxic. However, some organizations do not recommend its use, as it has been a subject of research and various speculation. Moreover, there have been some side effects of silver sulfadiazine such as loss of appetite, dizziness, and nausea.

Request PDF Brochure Of Research Report:https://www.coherentmarketinsights.com/insight/request-pdf/2763

Market Outlook

Global silver sulfadiazine market size is expected to increase significantly during to forecast period (2019-2027). Burn injuries are considered severe healthcare problems and far more serious than other epidemics such as polio. According to the World Health Organization, around 180,000 deaths occur due to burns, majorly in emerging economies. Furthermore, non-fatal burn injuries are the leading cause of morbidity. This is expected to increase the demand for anti-burn creams and lotions and subsequently drive the market growth. Furthermore, silver sulfadiazine has been majorly used hospitals in North America as it is considered as a powerful treatment for burns.

However, silver sulfadiazine causes minor side effects such as nausea, loss of appetite, and dizziness, which may hinder the demand for the product and subsequently restrain the global silver sulfadiazine market growth. Furthermore, increasing the price of silver, which is one of the prime raw materials for the production of silver sulfadiazine expected to hinder

Market Regional

North America is expected to account for the largest market share in the global silver sulfadiazine market, during the forecast period. This is owing to increased burn cases and increasing demand for wound-care products. According to the National Fire Protection Association (NFPA), around every two hours, a civilian die from fire outbreaks, which has increased the demand for wound-care products. Furthermore, increasing government initiatives to fund research and development of medicines to treat burn wounds has accelerated the market growth. Moreover, Asia Pacific is expected to witness significant growth in the market, owing to increasing demand for silver sulfadiazine from emerging economies such as India and China. The countries Australia, China, and India are expected to emerge as new revenue generators in the region.

Browse Complete Report For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/silver-sulfadiazine-market-2763

Market Players

Key players operating in the global silver sulfadiazine market include 3M Company, Baxter International, Inc., Monarch Pharmaceuticals, Teva Pharmaceutical Industries Ltd, and Johnson & Johnson Limited.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Nasal Polyps Treatment Market Growth And Latest Trends 2018-2026

Nasal polyps are benign growths occurring inside the paranasal sinuses and in the lining of the nose. Generally, it is characterized as a teardrop shaped and yellowish brown or pink in color. The size of the polyps may vary and can be clustered or may grow alone. These can cause severe infections and breathing difficulties, causing sleep apnea in some cases. The cause of nasal polyps can be due to asthma, allergic infections, sinus infections, cystic fibrosis, etc. There are no particular symptoms that develop but an inflammation in the lining of the nose can occur.

Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/2775

Global Nasal Polyps Treatment Market Drivers

Key players are constantly focused on developing novel approaches for treatment of nasal polyps, which is expected to impel the global nasal polyps’s treatment market growth. For instance, in April 2018, Intersect ENT Inc. launched a product, SINUVA. It is a sinus implant and used for treating nasal polyps. It is a new way of treatment in patients with the past sinus surgeries. This implant contains 1.35 mg mometasone furoate which is delivered, directly to the polyps. It is implanted for a definite period of time (90 days).

Furthermore, in June 2019, Novartis AG revealed the phase III clinical trial study of Xolair, Omalizumab. It is a monoclonal antibody used for treating nasal polyps. It tends to target and block the immunoglobulin E. It was observed that the medication was generally well-tolerated in patients. Hence, such developments of treatment for nasal polyps are expected to fuel the global nasal polyps treatment market growth.

Increasing approvals from regulatory bodies related to nasal polyps treatment is expected to drive the global nasal polyps treatment market growth. For instance, in June 2019, Dupixent received an approval from the U.S. Food & Drug Administration (FDA) for treating  with nasal polyps. It was manufactured by Sanofi in partnership with Regeneron Pharmaceuticals Inc. It is the first treatment that got approved for chronic rhinosinusitis with nasal polyps. It is used when the oral steroids are unable to control the inflammation and to avoid the surgical method. Hence, such approvals are expected to impact positively on the global nasal polyps treatment market growth.

Global Nasal Polyps Treatment Market Regional Analysis

North America is expected to hold a dominant position in the global nasal polyps treatment market. Factors such as higher prevalence of asthma is expected to be a major contributor in the North America’s nasal polyps treatment market growth. Nasal polyps are triggered due to asthma and also at the same time nasal polyps can cause asthma. For instance, according to American Academy of Allergy, Asthma & Immunology 2017, published data, around 28% to 40% patients with nasal polyps are diagnosed with asthma. According to the same source, around 19% to 39% patients get nasal polyps who are already suffering from asthma. Such increasing prevalence may increase the demand for treatment of nasal polyps thereby expected to propel the global nasal polyps treatment market growth.

Global Nasal Polyps Treatment Market Restraints

Side effects associated with the medication used for the treatment of nasal polyps may restrain the global nasal polyps treatment market growth. The mometasone furoate monohydrate can cause common side effects such as headache, sore throat, muscle and joint pain, nausea, and in some cases bleeding of nose. Hence, this factor may obstruct the global nasal polyps treatment market growth.

Browse Complete Report For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/nasal-polyps-treatment-market-2775

Global Nasal Polyps Treatment Market Key Players

Some of the major players operating in the global nasal polyps treatment market include, Intersect ENT Inc., GlaxoSmithKline Plc, Merck Sharp and Dohme Corp, Teva Branded Pharmaceutical Products R and D Inc., Norton Waterford Ltd, Sanofi, Regeneron Pharmaceuticals Inc., Fougera Pharmaceuticals Inc., Glenmark, and Taro Pharmaceuticals Industries Ltd.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Ostomy Care Market Growth And Latest Trends 2018-2026

Ostomy refers to a surgical procedure that allows the passage of bodily wastes through a surgically created stoma or aperture on the abdomen into a prosthetic such as a pouch or bag placed outside the body. Ostomy is performed on patients suffering from various medical conditions, including cancer, birth defects, diverticulitis, incontinence, and inflammatory bowel disease. This procedure is also performed on patients suffering from severe abdominal and pelvic trauma caused due to accidents or severe injuries. Ostomy is also known as continent diversion surgery and can be performed on patients of all age groups. The procedure does not affect life expectancy of an individual.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/1687

Ostomy leads to elimination of waste material from the body through stoma, which is part of the intestine that lacks presence of contraction muscles, thus resulting in loss of control of the individual on excretion of gas or solid waste from the body. The waste is automatically collected in a plastic bag or pouch that holds the waste and helps block the smell at the same time. Ostomy leads to rerouting of bodily waste from its usual path that can result due to malfunctioning parts of the digestive or urinary system. Depending on the severity of the patient, the ostomy can be temporary or permanent. The most common types of ostomies involve colostomy, ileostomy, urostomy, J-pouch, and continent urostomy among others.

Market Dynamics

The rising number of ostomy procedures being performed is the primary factor responsible for driving growth of the global ostomy care market. For instance, according to National Center for Biotechnology Information, around 100,000 people underwent operations resulting in colostomy or ileostomy in the U.S., in 2014. Increasing prevalence of inflammatory bowel disease is also expected to increase the demand for ostomy care. For instance, according to a research survey published in ‘The Lancet’ in October 2017, western countries suffer with a high prevalence of inflammatory bowel disease that has surpassed 0.3% of the total population. Moreover, according to the Worldwide Incidence and Prevalence of Inflammatory Bowel Disease (IBD) in the 21st Century: A Systematic Review of Population-Based Studies 2017, the incidence of IBD and Crohn’s disease is increasing in Latin America, Africa, and Asia Pacific. Various other factors responsible for the growth of market include rising incidence of bladder cancer, birth defects, and technological advancements. For instance, around 10,171 cases of bladder cancer were reported in the U.K. in 2015, out of which 50% cases survived through proper medication and care. However, low awareness in underdeveloped and developing economies regarding the availability of treatments and increasing pricing pressure on the manufacturer is expected to confine the market growth.

Regional Insights

On the basis of region, the global ostomy care market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds a dominant position in the global ostomy care market and is expected to retain its dominance over the forecast period, owing to large population suffering from Crohn’s disease, inflammatory bowel diseases, and other diseases in the region. According to the Centers of Disease Control and Prevention, around 1.3% of the adults in the U.S., accounting up to 3 million patients were reported to be suffering from inflammatory bowel disease in 2015 that increased the overall hospitalization rate in the country.

Furthermore, Asia Pacific is expected to witness a significant growth in the market, which is attributed to increasing efforts undertaken by government and non-government organization to support research, generate awareness, and increase the availability of treatment options to patients in their native countries. For instance, the Japan Ostomy Education is a non-profit organization approved by Ministry of Health, Labor and Welfare in Japan that conducts various activities concerned with stoma care for delivering a better life to patients suffering from related medical issues in Japan.

Browse Complete Report For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/ostomy-care-market-1687

Competitive Insights

Key players operating in the global ostomy care market include 3M Company, Coloplast Corporation, ConvaTec, Inc, Hollister, Inc., Smith & Nephew Plc, Alcare, Nu-Hope, Welland Medical, Cymed, and Flexicare Medical. Market players are focused on providing technologically advanced products, to sustain their position in the competitive market. For instance, in March 2015, Welland Medical introduced Aurum 2, a range of 2-piece ostomy pouches that is inclusive of flange with added medical grade Manuka honey.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702